VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related symptoms.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2024-08-31
DOI
https://doi.org/10.17615/cjs2-he71
Citations
1
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Dan-Yu Lin, Thomas R. Fleming
1 citations
UNC Libraries
COVID-19 Clinical Research Studies
article

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Dan-Yu Lin, Thomas R. Fleming
article en
1 citations

Abstract

To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related symptoms.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Zero hunger
Openalex Percentile: Top 82%
COVID-19 Clinical Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 — Dan-Yu Lin, Thomas R. Fleming · UNC Libraries (2024) | TGRS Research Map | TGRS